3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study
JACC: Cardiovascular Interventions · 2024
DOI: 10.1016/j.jcin.2024.05.017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Firas Zahr und 19 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland, Oregon, USA. Electronic address: zahr@ohsu.edu. Hauptthemen laut MEDLINE: Bicuspid Aortic Valve Disease, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Medtronic Inc.
Abstract (Originalsprache)
BACKGROUND: Outcomes from transcatheter aortic valve replacement (TAVR) in low-surgical risk patients with bicuspid aortic stenosis beyond 2 years are limited. OBJECTIVES: This study aimed to evaluate 3-year clinical and echocardiographic outcomes from the Evolut Low Risk Bicuspid Study. METHODS: The Evolut Low Risk Bicuspid Study is a prospective, multicenter, single-arm study conducted in 25 U.S. CENTERS: Patients with severe aortic stenosis at low surgical risk with bicuspid aortic valve anatomy (all subtypes) underwent TAVR with a self-expanding, supra-annular Evolut R or PRO (Medtronic) bioprosthesis. An independent clinical events committee adjudicated all deaths and endpoint-related adverse events, and a central echocardiographic core laboratory assessed hemodynamic endpoints. RESULTS: An attempted implant was performed in 150 patients from December 2018 to October 2019. The mean age was 70.3 ± 5.5 years, 48% (72/150) of the patients were women, and the mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 1.3% (Q1-Q3: 0.9%-1.7%). Sievers type 1 was the dominant bicuspid morphology (90.7%, 136/150). The Kaplan-Meier rates of all-cause mortality or disabling stroke were 1.3% (95% CI: 0.3%-5.3%) at 1 year, 3.4% (95% CI: 1.4%-8.1%) at 2 years, and 4.1% (95% CI: 1.6%-10.7%) at 3 years. The incidence of new permanent pacemaker implantation was 19.4% (95% CI: 12.4%-29.6%) at 3 years. There were no instances of moderate or severe paravalvular aortic regurgitation at 2 and 3 years after TAVR. CONCLUSIONS: The 3-year results from the Evolut Low Risk Bicuspid Study demonstrate low rates of all-cause mortality or disabling stroke and favorable hemodynamic performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oregon Health & Science University, Portland, Oregon, USA. Electronic address: zahr@ohsu.edu.
- Lankenau Heart Institute, Philadelphia, Pennsylvania, USA.
- Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
- University of Michigan Health Systems, University Hospital, Ann Arbor, Michigan, USA.
- OhioHealth Riverside Methodist Hospital, Columbus, Ohio, USA.
- Oregon Health & Science University, Portland, Oregon, USA.
Förderung
- Medtronic Inc
Zitieren
APA
Zahr, F., Ramlawi, B., Reardon, M. J., Deeb, G. M., Yakubov, S. J., Song, H. K., Kleiman, N. S., Chetcuti, S. J., Gada, H., Mumtaz, M., Leung, S., Merhi, W., Rovin, J. D., DeFrain, M., Muppala, M., Kauten, J., Rajagopal, V., Huang, J., Ito, S., & Forrest, J. K. (2024). 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.05.017
Vancouver
Zahr F, Ramlawi B, Reardon MJ, Deeb GM, Yakubov SJ, Song HK, et al. 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.05.017
BibTeX
@article{Zahr2024,
author = {Zahr, Firas and Ramlawi, Basel and Reardon, Michael J and Deeb, G Michael and Yakubov, Steven J and Song, Howard K and Kleiman, Neal S and Chetcuti, Stanley J and Gada, Hemal and Mumtaz, Mubashir and Leung, Stephane and Merhi, William and Rovin, Joshua D and DeFrain, Michael and Muppala, Murali and Kauten, James and Rajagopal, Vivek and Huang, Jiang and Ito, Saki and Forrest, John K},
title = {3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study},
journal = {JACC: Cardiovascular Interventions},
year = {2024},
doi = {10.1016/j.jcin.2024.05.017}
}
EUVIMED